Diabetic Retinopathy / Clinical Trials -- AAO DME in the Real World: Treatments Past, Present, and Future Pre-test

1
Based on the outcomes of the Phase III RIDE/RISE trial, what percentage of subjects needed zero injections?
2
In the outcomes of DRCR Protocol I steroids and anti-VEGF have the same impact as slowing the progression of PDR?
3
Based on the Open Label Extension study and the ENDURANCE extension study following the Phase III RIDE/RISE and VISTA/VIVID trials analyzing ranibizumab and aflibercept for DME management respectively, the mean number of anti-VEGF treatments administered in the 4th year of treatment was:
4
In the ENDURANCE Phase IV open-label study assessing the need for ongoing aflibercept, subjects maintained visual acuity gains achieved in the Phase III trial with significantly reduced dosing
5
Future studies in suprachoroidal delivery of sorticosteroids predict